Ozempic® is the latest innovation in type 2
diabetes treatment, offering patients a once-weekly medication that
helps bring their blood sugars under control and manage their
weight – with an established cardiovascular safety
profile.1,2
MISSISSAUGA, ON, March 5, 2018 /CNW/ - Novo Nordisk announced
today that Ozempic® (semaglutide injection) is now
available across Canada.
Ozempic® is a once-weekly glucagon-like peptide (GLP-1)
receptor agonist indicated alongside diet and exercise to improve
glycemic control in adults with type 2 diabetes when metformin is
inappropriate.1 Ozempic® can also be used
with other medications when diet and exercise is no longer
enough.1
"Type 2 diabetes is a complex and chronic condition," says Dr.
Jan Hux, President and Chief Science
Officer of Diabetes Canada. "Without adequate control, blood sugar
levels remain high and are associated with elevated risks of
complications such as stroke and heart attack. Therefore, it is
critically important that people with diabetes are provided with
solutions to address blood sugar control which reduce the risk of
complications, and are well tolerated."
Ozempic® is the result of one of the most robust
clinical research programs in type 2 diabetes. It is well studied
with more than 8,000 patients in the SUSTAIN phase 3a clinical
trial program.1
In head-to-head trials, Ozempic® consistently
demonstrated superior blood sugar control versus all comparators,
including all available once-weekly treatments.1,2
Overall, Ozempic® helped up to 79 per cent of
patients with type 2 diabetes reach their blood sugar
targets.1,2 Patients receiving Ozempic® also
experienced clinically significant weight loss of up to 14
lbs.1,2
"Ozempic® has an established cardiovascular safety
profile," explains Stephane Krummen,
Medical Director, Medical Affairs, Novo Nordisk Canada Inc. "No
increased risk of major adverse cardiovascular events was seen with
Ozempic®. In SUSTAIN 6, Ozempic® reduced the
risk of cardiovascular death, non-fatal heart attacks, and
non-fatal strokes by 26 per cent versus placebo; with standard of
care."
About Ozempic®
Ozempic® is a new
once-weekly analog of human GLP-1 designed to mimic natural sugar
metabolism by stimulating insulin and suppressing glucagon
secretion in a glucose-dependent manner.1
Ozempic® will be available in a prefilled pen, based on
the latest generation of Novo Nordisk prefilled devices.
Ozempic® had a well-tolerated profile across the
SUSTAIN clinical trial program with the most common adverse events
being generally mild to moderate gastrointestinal disorders, which
diminished over time.1
For information about Ozempic®, including important safety information, please visit http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Ozempic®-product-monograph.pdf.
About the SUSTAIN clinical trial program
SUSTAIN is a
global clinical trial program for Ozempic® comprised of
phase 3a clinical trials and a cardiovascular outcomes trial,
involving more than 8,000 adults with type 2
diabetes.1
Ozempic® demonstrated superior glycemic control
versus other treatments: sitagliptin (SUSTAIN 2) and dulaglutide
(SUSTAIN 7).1,2 In SUSTAIN 7, 79 per cent of patients
receiving Ozempic® reached their blood sugar
targets.2 On average, patients in SUSTAIN 7 lost 14 lbs
since starting the trial.2
Ozempic® demonstrated an established cardiovascular
safety profile in SUSTAIN 6. In this trial, patients receiving
Ozempic® had a 26 per cent reduced risk of
cardiovascular death, non-fatal heart attacks, and non-fatal
strokes versus placebo; with standard of care.1
About Novo Nordisk
Novo Nordisk is a global
healthcare company with more than 90 years of innovation and
leadership in diabetes care. This heritage has given us experience
and capabilities that also enable us to help people defeat obesity,
haemophilia, growth disorders and other serious chronic diseases.
Headquartered in Denmark, Novo
Nordisk employs approximately 41,700 people in 77 countries and
markets its products in more than 165 countries. For more
information, visit novonordisk.com, Facebook, Twitter, LinkedIn,
YouTube.
References
1. Ozempic® Product Monograph.
Novo Nordisk Canada Inc. January 4,
2018.
2. Pratley R, et al. Lancet Diabetes Endocrinol 2018;
doi:10.1016/S2213-8587(18)30024-X [Epub Ahead of Print].
SOURCE Novo Nordisk Canada Inc.